Suzetrigine

Suzetrigine (VX-548) is an orally active and highly selective NaV1.8 inhibitor that acts as an analgesic. Suzetrigine is also a blocker of sodium channel protein type 10 subunit alpha. Suzetrigine is promising for research of acute pain after abdominoplasty and bunionectomy[1][2][3][4][5].

Product Specifications

CAS Number

[2649467-58-1]

Product Name Alternative

VX-548

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/suzetrigine.html

Concentration

10mM

Purity

99.96

Solubility

DMSO : 116.67 mg/mL (ultrasonic)

Smiles

NC(C1=CC(NC([C@H]2[C@H](C3=C(C(F)=C(C=C3)F)OC)[C@@H]([C@@](C)(O2)C(F)(F)F)C)=O)=CC=N1)=O

Molecular Formula

C21H20F5N3O4

Molecular Weight

473.39

Precautions

H302, H315, H319

References & Citations

[1]WHO Drug Information-World Health Organization (WHO) .|[2]Jones J, et al. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain. N Engl J Med. 2023 Aug 3;389 (5) :393-405.|[3]Zhang H, et al. A simple and sensitive ultra-high performance liquid chromatography tandem mass spectrometry method for the quantitative analysis of VX-548 in monkey plasma: Method validation and application to pharmacokinetic study. Biomed Chromatogr. 2024 Jul;38 (7) :e5907. |[4]Yu G, et al. Gender difference in the pharmacokinetics and metabolism of VX-548 in rats. Biopharm Drug Dispos. 2024 Apr;45 (2) :107-114.|[5]Qin H, et al. Discovery of selective NaV1.8 inhibitors based on 5-chloro-2- (4,4-difluoroazepan-1-yl) -6-methyl nicotinamide scaffold for the treatment of pain. Eur J Med Chem. 2023 Jun 5;254:115371.